Bob Temple and others at the FDA dislike non-inferiority trials because a sponsor can fake the clinical results and still meet the primary endpoint with statistical significance. I’m not implying that anyone would actually do this, but it is theoretically possible.
Your point about having to cross-detail against one of the big pharma is a good one.
News 
Market Data 
Discover 
AI
